Denali Therapeutics

View All

Hunter Syndrome Market
Hunter Syndrome Market experiences a positive push as the pharma companies spot the untapped opportunities

The Hunter Syndrome Market is expected to grow with CAGR of 7.5% in the coming years in the 7MM. Occurring in approximately 1 in 100,000 to 1 in 170,000 male births, Hunter Syndrome, is an X-linked disorder, of carbohydrate metabolism that occurs almost exclusively in males, with females as the carriers of the d...

Find More

Parkinson’s Disease: 5 stages, Risk Factors, Prevention, Gene Therapy

Parkinson’s Disease is a condition that involves dysfunction or loss of dopamine-producing neurons in the brain. The hallmarks of this Disease are degeneration of dopaminergic neurons in the substantia nigra pars compacta of the midbrain and Lewy bodies presence, cytoplasmic aggregations of the protein a-synuclein ...

Find More

Denali’s Impressive Research Portfolio

The South San Francisco biotech startup, Denali Therapeutics, that had raised $217 million last year to fight Alzheimer’s, Parkinson’s and ALS, and an additional  $130 million from investors in a private placement led by Baillie Gifford, a UK-based mutual fund, has finally spoken about its plans to use the fund. The...

Find More